Why We're Buying Denmark's Novo Nordisk AS (NVO)
Thursday, September 18, 2014 3:26 PM EDT
Novo Nordisk AS, with a 90-year-old world diabetes treatment franchise, is getting into the related business of treating obesity. It expects FDA approval for its injectable obesity drug, Saxenda. Our analysis follows...
In this article: NVO